Suvorexant Acutely Decreases Tau Phosphorylation and Aβ in the Human CNS

Keyphrases

• Acute Effects 10%
• Alzheimer's Disease 20%
• Amyloid Plaques 10%
• Central Nervous System 10%
• Cerebrospinal Fluid 10%
• Chronic Treatment 10%
• Co-immunoprecipitation (co-IP) 10%
• Cognitive Symptoms 10%
• Cognitively Unimpaired 10%
• Drug Administration 10%
• Drug Repurposing 10%
• Insomnia 10%
• Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS) 10%
• Lumbar Catheter 10%
• Mouse Model 10%
• Neurofibrillary tau Tangles 10%
• Neuronal Loss 10%
• Orexin Receptors 20%
• Overexpressing 10%
• Paired Helical Filaments 10%
• Phospho-tau 20%
• Phosphorylated tau 20%
• Phosphorylation 20%
• Phosphosites 10%
• Placebo 40%
• Randomized Controlled Trial 10%
• Suvorexant 100%
• Tau Amyloid 10%
• Tau Phosphorylation 100%
• Threonine 30%
• U.S. Food 10%

Neuroscience

• Alzheimer's Disease 20%
• Amyloid Protein 70%
• Artificial Neural Network 10%
• Central Nervous System 10%
• Dual Orexin Receptor Antagonist 20%
• Immunoprecipitation 10%
• Liquid Chromatography-Mass Spectrometry 10%
• Placebo 40%
• Randomized Controlled Trial 10%
• Serine 10%
• Suvorexant 100%
• Threonine 30%